Effects of endocannabinoids on feed intake, stress response and whole-body energy metabolism in dairy cows

Isabel van Ackern1, Ramona Wulf2, Dirk Dannenberger3, Armin Tuchscherer4 & Björn Kuhla1*

Endocannabinoids, particularly anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are instrumental in regulating energy homeostasis and stress response. However, little is known about the endocannabinoid system (ECS) in ruminants, although EC could improve dairy health and productivity, at least by increasing feed intake. In this study, we report if intraperitoneal (i.p.) AEA and 2-AG administration affects feed intake, whole-body macronutrient metabolism, isolation and restraint stress, and whether diet composition modulates circulating endocannabinoid concentrations in cows. Twenty Simmental cows in late lactation were fed a grass silage and a corn silage based diet. On each diet, cows received daily i.p. injections with either AEA (5 µg/kg; n = 7), 2-AG (2.5 µg/kg; n = 6) or saline (n = 7) for 8 days. Endocannabinoid administration for 5 days under free-ranging (non-stressed) conditions had no effect on feed intake or energy balance, but attenuated the stress-induced suppression of feed intake when housing changed to individual tie-stalls without social or tactile interaction. Endocannabinoids increased whole-body carbohydrate oxidation, reduced fat oxidation, and affected plasma non-esterified fatty acid concentrations and fatty acid contents of total lipids. There was no effect of endocannabinoids on plasma triglyceride concentrations or hepatic lipogenesis. Plasma AEA concentrations were not affected by diet, however, plasma 2-AG concentrations tended to be lower on the corn silage based diet. In conclusion, endocannabinoids attenuate stress-induced hypophagia, increase short-term feed intake and whole-body carbohydrate oxidation and decrease whole-body fat oxidation in cows.

The endocannabinoid system (ECS) is a complex network ubiquitously expressed throughout the body. The best studied endocannabinoids (EC) N-arachidonylethanolamide (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) are synthesized from membrane phospholipids, with fat depots providing an important source for plasma EC1. Due to their amphiphilic character, EC can modulate the activity of many membrane proteins and activate the G protein-coupled cannabinoid receptors 1 and 2 (CB1 and CB2) or the G protein-coupled receptor 55 (GPR55), all of them expressed at the cell surface2,3. Primary enzymes degrading EC are fatty acid amide hydrolase (FAAH) for the breakdown of AEA and monoglyceride lipase (MGLL) for the degradation of 2-AG. Thus, FAAH and MGLL are involved in decreasing the EC tone, contributing to the short half-life of 2-AG and AEA of only a few minutes in mice4,5.

In rodents, a plethora of studies have shown that EC play an important role in the regulation of energy homeostasis6 involving the control of energy intake7–9 and energy expenditure10. The administration of AEA and 2-AG has been shown to stimulate feed intake of rats not only by acting at central but also peripheral sites. The injection of AEA or 2-AG into the brain11,12 as well as into the peritoneal cavity13 increased feed intake of rodents for a few hours. Peripherally administered EC may rapidly cross the blood–brain barrier14 or can activate vagal afferents in the periphery, thereby triggering signaling of the gut-brain axis15–17. The endogenous AEA and 2-AG tone in mice can be increased by diets supplemented with EC precursors such as arachidonic acid or...
linoleic acid\(^{18,19}\). By contrast, dietary lipids with higher content in n-3 polyunsaturated fatty acids (n-3 PUFA) can reduce the EC tone and diminish CB\(_1\) receptor activation in mice\(^{20}\).

In addition, EC are further involved in the regulation of the hypothalamic–pituitary–adrenal (HPA) axis\(^{21}\), which in turn affects not only energy metabolism but also stress response. Restraint stress has been demonstrated to decrease the AEA, but increase the 2-AG content in the amygdala of rats\(^{22,23}\). Moreover, pharmacological enhancement of EC signaling has been shown to attenuate the response to restraint stress in rodents by reducing corticosterone release\(^{24,25}\). Furthermore, EC support anabolic metabolism by promoting fat storage and decreasing energy expenditure\(^{26}\). More specifically, activation of CB\(_1\) stimulates lipogenesis in adipose cells\(^{27}\) and induces the expression of the lipogenic transcription factor steroid regulatory element-binding protein 1c (SREBP-1c) and its targets acetyl-CoA carboxylase-1 (ACC1) and fatty acid synthase (FAS) in liver\(^{28}\). However, knowledge about the involvement of the ECS in whole-body energy metabolism is mainly obtained from studies using CB\(_1\) antagonists (e.g. rimonabant, which is known to exert unwanted side effects) or CB\(_2\), KO mice\(^{29,30}\), but there is scarcity of studies using the natural endogenous receptor agonists.

As proposed by Myers, et al.\(^{31}\), activating the ECS in cows could provide the opportunity to improve dairy health and increase productivity by increasing feed intake and improving energy partitioning. Previous studies in periparturient dairy cows have shown the involvement of the ECS in adipose tissue metabolism, more specifically, an activation of the ECS in animals exhibiting high rates of lipolysis\(^{32}\). Furthermore, it has been shown that increased plasma AEA and 2-AG concentrations are directly associated with feed intake of dairy cows\(^{33}\), however, a direct cause-effect relationship has not been demonstrated yet. Also, feeding a ration above energetic requirements increased the expression of the CB\(_2\) receptor in bovine liver\(^{25}\), but whether the diet composition affects the EC tone, or how EC affect hepatic fat metabolism in ruminants is not known.

The aim of the present study was to evaluate the effect of i.p. administered AEA and 2-AG administration on isolation and restraint stress, feed intake, milk yield, whole-body macronutrient and hepatic fat metabolism in dairy cows, and to investigate if these effects are influenced by feeding a grass silage (GS) compared to a corn silage (CS) based diet. Given the fact that the n-6/n-3 ratio is typically higher in CS than GS and that increased dietary n-3 PUFA reduce the EC tone, we hypothesized that the effect of EC administration would be more pronounced on the CS diet.

**Methods**

**Animals and experimental design.** Experiments were performed at the Research Institute for Farm Animal Biology (FBN), Dummerstorf, Germany and were in accordance with the ARRIVE guidelines (https://arriveguidelines.org), the German Animal Welfare Act and approved by the ethics committee of the State Government in Mecklenburg-Western Pomerania, Germany (Registration No. LLALF M-V 7221.3-1.1-041/18). Twenty non-pregnant Simmental cows from 1st to 10th lactation, in late lactation with an average milk yield of 15.6 ± 0.2 L per day and 263 ± 22 days in milk (DIM) were adapted to the experimental facilities for at least 20 days. The experiment was set up as a randomized block with a split plot of diet type (Supplementary Fig. S1), where animals entered the experimental trial in 5 blocks of four animals each. One block experiment lasted for 8 weeks and consisted of both 4-week feeding periods. Diets were fed in a cross over design, and the first 20 days of the second feeding period was considered the washout period. The cows were kept in a free-ranging barn and received two total mixed rations (TMR, Supplementary Table S1) based on either GS (low n-6/n-3 ratio) or CS (high n-6/n-3 ratio) with an average metabolizable energy (ME) of 10.7 ± 0.2 and 11.5 ± 0.1 MJ/kg of dry matter (DM), respectively. Troughs were filled at 05:00 a.m. and again at 05:00 p.m. Access to ad libitum intake was restricted between 05:00 a.m. and 08:00 a.m. to ensure a comparable start of feed intake. Milking took place twice daily (05:30 a.m. and 05:30 p.m.) and the milk yield was recorded. Body weight (BW) was automatically restricted between 05:00 a.m. and 08:00 a.m. to ensure a comparable start of feed intake. Milking took place twice daily (05:30 a.m. and 05:30 p.m.) and the milk yield was recorded. Restraint stress has been demonstrated to decrease the AEA, but increase the 2-AG content in the amygdala of rats\(^{22,23}\). Moreover, pharmacological enhancement of EC signaling has been shown to attenuate the response to restraint stress in rodents by reducing corticosterone release\(^{24,25}\). Furthermore, EC support anabolic metabolism by promoting fat storage and decreasing energy expenditure\(^{26}\). More specifically, activation of CB\(_1\) stimulates lipogenesis in adipose cells\(^{27}\) and induces the expression of the lipogenic transcription factor steroid regulatory element-binding protein 1c (SREBP-1c) and its targets acetyl-CoA carboxylase-1 (ACC1) and fatty acid synthase (FAS) in liver\(^{28}\). However, knowledge about the involvement of the ECS in whole-body energy metabolism is mainly obtained from studies using CB\(_1\) antagonists (e.g. rimonabant, which is known to exert unwanted side effects) or CB\(_2\), KO mice\(^{29,30}\), but there is scarcity of studies using the natural endogenous receptor agonists.

On day 6 of each treatment period, cows were transferred from the free-ranging barn into open-circuit respiration chambers and kept in individual tie-stalls\(^{49}\) to induce isolation and restraint stress. Cows were fitted with an indwelling jugular vein catheter (Cavafix Certo Splittocan 338, B. Braun Melsungen AG, Melsungen, Germany) connected to a 4-m extension line to allow for blood sampling from outside of the chamber without disruption of gas exchange measurements and animal behavior. After over-night equilibration,
gas exchange measurement started on day 7 at 07:00 a.m. and lasted for 2 consecutive 24 h-periods at 15 °C. Intraportal injections were administered at 08:00 a.m., and animals were fed immediately after injection and again at 05:00 p.m. for ad libitum intake. Milking in the chamber was performed at 06:00 a.m. and 04:00 p.m. Feed intake was measured as feed disappearance from trough by an electronic registration device (PAARI, Erfurt, Germany) every 6 min. The CO₂ and CH₄ concentrations were analyzed by infrared absorption (SIDOR, Sick AG, Reute, Germany) and O₂ concentration was analyzed paramagnetically (SIDOR) in 6-min intervals. The airflow through the chamber (approximately 10 m³/h) was measured by a differential pressure type V cone flow meter (McCrometer, Hemet, CA). The mean CO₂ recovery rate for all 4 chambers was 99.9%.

For the following calculations, data were used as mean of both 24 h-periods. Total CO₂ production (CO₂ total) is the sum of fermentative CO₂ (CO₂ ferm) and metabolic CO₂ (CO₂ meta). CO₂ ferm was estimated according to Chwalibog et al.⁴⁰ as CO₂ ferm (L) = 1.7 × CH₄ (L) in which 1.7 is constant for a variety of diet compositions.⁴¹ Therefore, CO₂ meta was calculated by subtracting CO₂ ferm from CO₂ total.⁴² Net carbohydrate oxidation (COX) and net fat oxidation (FOX) were calculated by equations described by Frayn⁴³:

\[
\text{COX} (\text{g}) = 4.55 \text{CO}_2 \text{meta} (\text{L}) - 3.21 \text{O}_2 (\text{L}) - 2.87 \text{Nu} (\text{g})\
\text{FOX} (\text{g}) = 1.67 \text{O}_2 (\text{L}) - 1.67 \text{CO}_2 \text{meta} (\text{L}) - 1.92 \text{Nu} (\text{g})
\]

The metabolic heat production (HP) was calculated according to Brouwer⁴⁴:

\[
\text{HP (kJ)} = 16.18 \text{O}_2 (\text{L}) + 5.02 \text{CO}_2 \text{total} (\text{L}) - 2.17 \text{CH}_4 (\text{L}) - 5.99 \text{Nu} (\text{g})
\]

Urinary N excretion (Nu) was not measured but estimated to 100 g/d, although real Nu may vary from 75 to 150 g/d⁴⁵, thereby accepting an error in HP, COX and FOX of less than 10%.

Indirect calorimetry data was normalized to mBW and to account for individual differences among animals changes of FOX, COX, and HP were calculated relative to the start of each measurement period (07:00 a.m.). The resulting ΔFOX/mBW, ΔCOX/mBW, and ΔHP/mBW data were evaluated in hourly intervals between 07:00 a.m. and 05:00 a.m. of the following morning. In addition, daily values of FOX, COX and HP were adjusted to DMI and mBW.

**Feed and milk analyses.** Dry matter (DM) content of feed was determined weekly by dried pooled feed samples for 24 h at 60 °C followed by 4 h at 103 °C. Dry matter intake (DMI) was calculated from daily feed intake and weekly determined feed DM. During respiration chamber measurements, additional samples were taken for chemical analysis of nutrient composition. Chemical composition was analyzed by the accredited laboratory of Landwirtschaftliche Untersuchungs- und Forschungsanstalt der LMS Agrarberatung GmbH (LUFA, Rostock, Germany; Supplementary Table S1). The metabolizable energy (ME) content of the diet was calculated according to the German Society of Nutrition Physiology (GfE⁵⁰:

\[
\text{EB (MJ of ME/d)} = \text{MEI} - (3.14 \times \text{ECM} + 0.488 \times \text{mBW})
\]

Energie balance (EB) was estimated according to the GfE⁵⁰: EB (MJ of ME/d) = MEI – (3.14 × ECM + 0.488 × mBW).

For analysis of DMI/mBW, EB, and ECM data were calculated as means during the pre-treatment period (PB, day −5 to 0), treatment under normal, non-stressed housing conditions in the barn (TB, day 1 to 5) and treatment under stressed housing conditions in the respiration chamber (TC, day 7 and 8). Additionally, percent changes from PB to TB and TC were calculated.

**Blood sampling and analyses.** To evaluate changes in fat metabolism, preprandial blood samples were collected on day 1 and day 9 at 07:00 a.m., each before EC administration in EDTA-containing tubes. Blood samples were immediately placed on ice and centrifuged at 1570 × g for 20 min at 4 °C, and obtained plasma was stored at −80 °C. Plasma free, non-esterified fatty acid (NEFA), triglyceride (TG) and cholesterol concentrations were analyzed spectrophotometrically with a semi-automatic analyzer (ABX Pentra 400, HORIBA Medical, Kyoto, Japan) using the following kits: NEFA-HR 91797 (FUJIFILM Wako Chemicals Europe GmbH, Neuss, Germany), Triglycerides CP A11A01640 (HORIBA) and Cholesterol mono ChOD/PAP 900300 (mti-diagnostics GmbH, Idstein, Germany). The analysis of individual fatty acid concentrations in total plasma lipids was performed according to Dannenberger et al.⁵¹. Lipids were extracted by adding 1500 µL of plasma sample to a solution of chloroform/methanol (2:1, v/v) and internal standard (C19:0) at room temperature. Extracted lipids were methylated using sodium methylate and boron trifluoride methanol, and major fatty acids detected are listed in Supplementary Table S4. For analysis of individual changes in plasma lipid metabolites percent changes were calculated from pre-treatment to after 8 days of treatment.
For the analysis of plasma EC concentrations, plasma samples collected on day 8 prior to morning feeding and treatment were analyzed for AEA and 2-AG using the cross-validated method as described by Zoerner et al.². Briefly, 18-µL of an ethanolic solution of the internal standards d5-2-AG (53.3 pg/µL) and d4-AEA (50 pg/µL) were added to the thawed plasma samples and incubated for 15 min on ice. Solvent extraction was performed by adding toluene (1 mL) and by shaking twice in a Precellys 24 Dual Homogenisator at 5000 rpm for 20 s. Phase separation was achieved by centrifugation (4655 × g, 4 °C, 5 min). The upper organic phase was evaporated at room temperature under nitrogen. To the residue a 40-µL aliquot of water–methanol (1:3, v/v) was added and mixed by vortexing for 10 s. Analyses were performed on a Waters ACQUITY UPLC-MS/MS system with a tandem quadrupole mass spectrometer XEVO TQ MS (Waters, Milford, MA, USA). Separation of analytes was carried out on a Waters ACQUITY BEH C18 column (100 mm × 2.1 mm i.d., 1.7 µm particle size) at 60 °C.

Liver tissue, RNA extraction and RT-qPCR. On day 9 of EC treatment of the second feeding period, cows were stunned with a captive bolt gun and immediate exsanguinated at the institute’s slaughterhouse. Liver samples were taken and immediately snap frozen in liquid nitrogen and stored at − 80 °C until further analysis. Tissue samples were ground under liquid N. RNA was extracted from 20 to 25 mg tissue powder with innuPREP RNA Mini Kit 2.0 (Analytik Jena AG, Jena, Germany) and residual DNA was removed with innuPREP DNase I Digest Kit (Analytik Jena AG). RNA concentrations were quantified spectrophotometrically on a NanoPhotometer (Implen GmbH, Munich, Germany). RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), yielding RNA integrity number (RIN) factors between 7.0 and 8.7 (mean 7.7 ± 0.13). For cDNA synthesis, 750 ng total RNA was reverse transcribed (SensiFAST cDNA Synthesis Kit, Bioline, London, UK) using a ThermoCycler (peqstar 96 × HPL, VWR International, Pennsylvania, USA). Transcriptional expression was quantified by real-time PCR (qPCR) using the following primers (Supplementary Table S2). qPCR was performed on a LightCycler 2.0 (Roche, Basel, Switzerland) with SensiFAST SYBR No-ROX Kit (Bioline) with 2 µL of cDNA. Each cDNA sample was analyzed in duplicate. Primer products were sequenced and the correct sequence was confirmed. The efficiency of amplification was calculated using LinRegPCR software, version 2014.4 (Academic Medical Centre, Amsterdam, Netherlands), yielding efficiency values between 1.84 and 1.92 (Supplementary Table S2). Data were quantified by qbasePlus software (Biogazelle, Gent, Belgium) and normalized to the reference genes eukaryotic translation initiation factor 3 subunit K (EIF3K) and peptidylprolyl isomerase A (PPIA).

Statistical analyses. Data were analyzed with mixed models (PROC MIXED) and repeated measures using SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA). Unless otherwise stated, the random effects of all models were block and block by period interaction and a compound symmetry covariance structure was used for all data. Denominator degrees of freedom were estimated by using the Satterthwaite option in the MODEL statement and paired differences were determined using the SLICE option in PROC MIXED.

The DMI/mBW, EB, ECM, and percent changes in DMI/mBW, EB, ECM were analyzed with the fixed effects of treatment, housing, diet and all associated interactions. Housing was used in the repeated statement to account for repeated measures and the subject was defined as cow by period interaction. The AFOX/mBW, ΔCOX/mBW, and ΔHP/mBW were analyzed with the fixed effects of treatment, time interval, diet and all associated interactions. Time interval was used in the repeated statement and the subject was defined as cow by period interaction.

The FOX, COX and HP values adjusted to DMI and mBW as well as the percent changes in plasma lipid metabolites data were analyzed with the fixed effects of treatment, diet and their interaction. Period was used in the repeated statement and the subject was defined as cow. The mRNA abundances of hepatic genes were analyzed with the fixed effect of treatment and the random effect of block.

Plasma AEA and 2-AG concentrations were analyzed using the t-test procedure of SAS. Data were tested for a normal distribution with a Shapiro–Wilk test and transformed using the Johnson transformation prior to testing if necessary. Transformed data are noted in the table. Calculation of Pearson correlation between dietary fatty acids and EC concentrations was performed by using the CORR procedure of SAS. Significance was declared at $P \leq 0.05$ and tendencies were declared at $0.05 < P \leq 0.10$. Results are presented as LSM ± SE unless stated otherwise.

Results

Dry matter intake, energy balance and energy corrected milk yield. DMI normalized to mBW, EB and ECM did not differ between groups pre-treatment (PB) (Supplementary Fig S2A) and were higher on the CS than GS diet ($P < 0.05$). However, the diet had no effect on the treatment and there was no three-way interaction of diet, treatment and housing. The analysis of individual changes in DMI/mBW revealed that the i.p. EC treatment under normal, non-stressed conditions in the barn (TB) for 5 days had no effect (Fig. 1a). Continuation of treatments but housing change to respiration chambers (TC) inducing isolation and restraint stress decreased DMI/mBW in all groups compared to PB ($P < 0.001$). However, the reduction in DMI/mBW from PB to TC was only 8.6 ± 3.6% with AEA and 9.6 ± 3.8% with 2-AG treatment, and was significantly less ($P < 0.01$) than in the control group (22.4 ± 3.6%, Fig. 1a). Consistent with changes in DMI/mBW, i.p. EC treatment TB had no effect on EB (Fig. 1b) and when cows were exposed to the stressful environment, EB declined ($P < 0.001$). The decline in EB was only 15.8 ± 12.6% with AEA, 28.4 ± 13.0% with 2-AG, but 60.0 ± 12.6% in the control group ($P < 0.05$, Fig. 1b). Equally, ECM was not affected by i.p. EC treatment TB and declined with change of housing to TC ($P < 0.001$; Fig. 1c). The reduction in ECM from PB to TC was 7.8 ± 3.0% with AEA, 2.5 ± 3.1% with 2-AG, but 11.7 ± 3.0% in the control group. The reduction in the control group was significantly greater than in the 2-AG group ($P < 0.05$).
Plasma lipids. The analysis of plasma lipid concentrations revealed some differences among animals before EC treatment, therefore, we analyzed the individual changes from PB to TC. The percent changes in plasma NEFA concentrations were different between treatment groups ($P < 0.001$) (Fig. 2a). While plasma NEFA concentrations significantly decreased after 8 days of treatment with AEA compared to the control group ($P < 0.001$) and tended to increase to a lesser extend with 2-AG treatment compared to the control group ($P = 0.05$). No changes were detected for percent changes in plasma TG. Plasma cholesterol percent changes differed in the control group between diets, as indicated by the treatment x diet interaction ($P < 0.05$). Graphs are presented as highest level of significant interaction, associated $P$-values can be found in Supplementary Table S3. Treatment differences are indicated by $\# < 0.1$, $^* P < 0.05$ and $*** P < 0.001$ (Tukey–Kramer).

Among total lipids, the plasma palmitic acid (C16:0) content increased in the control group but declined in the AEA and 2-AG groups on both diets ($P < 0.01$; Supplementary Table S4). The oleic acid (C18:1n9) content also increased in the control group but remained unchanged in EC-treated animals on the GS diet and declined in EC-treated animals on the CS diet ($P < 0.01$). Palmitoleic acid (C16:1n7) content was affected by treatment ($P < 0.05$), with a greater decrease in the AEA and 2-AG compared to the control group. In contrast, linoleic acid (C18:2n6) was ($P < 0.01$) and stearic acid (C18:0) tended to be ($P = 0.09$) reduced in NaCl but increased or unchanged in EC-treated cows (Supplementary Table S4). Plasma arachidonic acid (C20:4n6) contents were not different between treatment groups. However, the contents of C20:4n6, C20:2n6, C20:3n6 and C22:4n6 tended to increase on the CS diet ($P < 0.1$). Percent changes in the plasma $n−6/n−3$ ratio tended to be different between treatment groups ($P = 0.05$) (Supplementary Table S4).
Whole body energy metabolism. Next, we examined short-term effects of EC on feed intake and whole body energy metabolism. The BW, body condition score and back fat thickness did not differ between groups (data not shown). DMI/mBW was not different between the GS and CS diet (Supplementary Table S3). Hourly DMI/mBW changed over time ($P<0.001$) and differed between treatment groups ($P<0.05$; Fig. 3a). Specifically, within the 1st h after injection, i.p. AEA and 2-AG administration resulted in a 33.8 and 49.7% higher DMI/mBW compared to the control group ($P<0.001$). Subsequently, hourly DMI/mBW was not significantly different between groups. Cumulative DMI/mBW increased over time ($P<0.001$) and tended to be different between treatment groups ($P=0.05$; Fig. 3b). Within 8 h after i.p. injection and morning feeding, AEA and 2-AG treatment resulted in a 29.6 and 33.0% increase in cumulative DMI/mBW compared to the control group ($P<0.05$). Effects of the EC treatments were no longer observed after the afternoon feeding at 05:00 p.m. Fat oxidation (FOX) ranged from -2.0 to 14.7 g per 6 min on the GS and from -4.6 to 10.2 g per 6 min on the CS diet (data not shown). The Δ FOX/mBW varied over time ($P<0.001$; Fig. 3c) and was lower on the CS than GS diet ($–0.16$ vs $0.09$ g x kg$^{-1}$ x kg$^{-0.75}$; $P<0.05$). AEA treatment resulted in a greater decrease in Δ FOX in the first 2 and 10th h after injection and was significantly lower than in the control group ($P<0.05$). Likewise, 2-AG treatment resulted in a greater decrease in Δ FOX in the first 2 h and 10 to 12 h after injection and was significantly lower than in the control group ($P<0.05$; Fig. 3c). Carbohydrate oxidation (COX) ranged from $–4.8$ to $47.1$ g per 6 min on the GS and from $3.9$ to $52.2$ g per 6 min on the CS diet (data not shown). Δ COX/mBW varied over time ($P<0.001$) and was different between treatment groups ($P<0.01$; Fig. 3d). Specifically, i.p. EC injection resulted greater increase in Δ COX/mBW with AEA and 2-AG treatment compared to control treatment (Fig. 3d). The increase in Δ COX/mBW was significantly higher with AEA treatment 1 to 3, 5 to 14 and 19 h and with 2-AG treatment 2, 5 to 7, 10 and 13 to 14 h after injection relative to the control ($P<0.05$). Metabolic heat production (HP) normalized to mBW ranged from 380.4 to 740.7 kJ per 6 min on the GS and from 398.5 to 839.4 kJ per 6 min on the CS diet (data not shown). A HP/mBW was greater on the GS than CS diet (2.11 vs $0.02$ kJ x kg$^{-1}$ x kg$^{-0.75}$; $P<0.001$), changed over time ($P<0.001$; Fig. 3e) and was different between treatment groups ($P<0.01$; Fig. 3e). The i.p. AEA and 2-AG injections resulted in a greater increase in Δ HP/mBW. Specifically, the increase was significantly higher 3, 5 to 15 and 18 to 20 h after AEA treatment and 7 h after 2-AG treatment relative to the control ($P<0.05$).

To account for the difference in feed intake among groups during indirect calorimetry, daily FOX, COX and HP were additionally normalized to individual DMI. FOX per mBW and DMI tended to be greater on the GS than the CS diet (0.66 vs $0.33$ g x kg$^{-1}$ x kg$^{-0.75}$; $P=0.09$). Double normalized FOX tended to be different between treatment groups ($P=0.08$; Fig. 3f) and was 32.9% lower with AEA ($P<0.01$) and 33.5% lower 2-AG ($P=0.12$) compared to the control group. Double normalized COX tended to be higher on the GS than the CS diet (2.67 vs $2.08$ kJ x kg$^{-1}$ x kg$^{-0.75}$; $P=0.05$), but was not different between treatment groups (Fig. 3g). Double normalized metabolic HP was neither different between diets nor treatment groups (Fig. 3h).

Transcription of Hepatic Genes. The analysis of the mRNA abundance of hepatic genes involved in the ECS (CNR1, FAAH, MGLL, GPR55) and fat metabolism (ACAA2, ACACA, CPT1A, DGAT1 and 2, HADH, PLAAT5, PPARα and SREBF1) revealed no differences between treatment groups (Table 1).

Plasma endocannabinoid concentrations. We next examined if the diet composition affected the basal plasma EC concentrations. As shown in Table 2, pre-treatment plasma AEA concentration of all cows was not affected by diet composition, however, plasma 2-AG concentrations tended to be 36% lower when animals were fed the CS diet ($P<0.10$). There were no significant correlations between dietary fatty acids and plasma EC concentrations (data not shown).

Discussion Effect of endocannabinoids on dry matter intake, energy balance, and isolation and restraint stress. Many studies have shown that EC regulate feed intake in rodents[7,13,35]. To the best of our knowledge, this is the first study describing the effects of i.p. administered AEA and 2-AG on feed intake and energy metabolism in lactating dairy cows. We found that administration of EC for 5 days did not alter daily feed intake when animals were kept under free ranging (non-stressed) conditions in a barn. The lack of feed intake response may be due to a too short administration period of 5 days, a high diurnal temperature variability in the barn, social competition over preferred feeding troughs, or because short-term changes in feed intake could not be detected on the daily measurement basis (see below). With change of housing and induction of restraint stress, DMI/mBW decreased in all groups consistent with the stress-induced hypophagia in rodents and humans[33,34]. In fact, isolation of cows without social and tactile interaction has been shown to induce stress, increasing plasma cortisol and decreasing feed intake[35,36]. Furthermore, stress is exacerbated by confinement and tethering[35,37]. In another reason for the decline in feed intake is the lower energy requirement for physical activity when animals are tie-stalled. However, the decline in feed intake with housing change was significantly less with EC treatments, indicating that AEA and 2-AG administration improved habituation and attenuated the stress response. Activation of the ECS by administering the CB1 agonist CP55940 or the FAAH inhibitor URB597 has shown to inhibit the restraint-induced activation of the HPA axis in mice[24]. Furthermore, CP55940 and URB597 blocked the restraint stress-induced decrease in sucrose consumption of mice[38] and ameliorated stress[39]. Although we did not measure EC when cows were kept under normal, non-stressed housing conditions, plasma 2-AG concentrations were approximately 20- to 30-fold higher during isolation and restraint stress than basal levels of cows housed in a free-ranging, non-stressed environment[38], further underscoring the involvement of EC in response to stress. Energy balance and ECM also decreased along with housing and stress level change which can be attributed to the decrease in feed intake. Furthermore, the decline in energy balance was significa


Figure 3. Hourly dry matter intake (DMI) per mBW (a), cumulative DMI/mBW (b), changes in fat oxidation per mBW (Δ FOX/mBW) (c), changes in carbohydrate oxidation per mBW (Δ COX/mBW) (d), changes in heat production per mBW (Δ HP/mBW) (e) and daily fat oxidation (FOX) (f), carbohydrate oxidation (COX) (g) and heat production (HP) (h), each normalized to dry matter intake (DMI) and metabolic bodyweight (mBW). Cows were intraperitoneally injected with either NaCl (n = 7), AEA (n = 7) or 2-AG (n = 6). Feed was withheld from 07:00 to 08:00 a.m. The star indicates the i.p. injection (08:00 a.m.), the arrow indicates feeding at 08:00 a.m. and 05:00 p.m. Graphs are presented as highest level of significant interaction, associated P-values can be found in Supplementary Table S3. Treatment differences between the control and AEA group are indicated by * (P < 0.05; Tukey–Kramer), and differences between the control and 2-AG group are indicated by ** (P < 0.05; Tukey–Kramer).
with EC treatment, thus the extent of energy balance reduction can be ameliorated by EC treatment preventing an excessive decline in energy intake.

Additionally to a stress-protective role, AEA and 2-AG administration also increased feed intake during indirect calorimetry in the short-term. The 6-min recordings showed that immediately after AEA and 2-AG injection at dosages of 5 and 2.5 µg/kg, respectively, feed intake was higher than in controls for the first hour after injection only. This short-term response may explain why we did not observe differences in daily feed intake measured in the barn. The short-term effect could be due to the observed short half-life of AEA and 2-AG of only a few minutes in heparinized mouse blood5. Because the half-life of 2-AG was higher in human plasma compared to rat plasma, a different half-life between various mammals can be assumed60. The specific half-life of AEA and 2-AG in cows is not known and needs to be determined in future studies. However, plasma AEA concentrations of the cows studied were 2.5-fold increased 2.5 h after i.p. administration of 5 µg AEA/kg BW61. This finding indicates that AEA accounts for the increase in feed intake despite of its relative short half-life and further suggests that the half-life of AEA in cows is presumably not as short as it is in mice. A short-term (1 to 3 h) increase in feed intake was also observed after subcutaneous administration of 0.5 to 10 mg/kg AEA to rats7. However, other studies performed in mice reported that AEA35 and 2-AG9 each administered i.p. at 0.001 mg/kg, increased cumulative feed intake over 7 or 14 days, respectively. Higher dosages tested by these authors, e.g. 0.7 and 4 mg/kg AEA35, or 0.01 and 0.1 mg/kg 2-AG7 had no long-term effect on cumulative feed intake in mice. Future studies are needed to determine if higher EC dosages or multiple injections per day would increase feed intake also in the long-term, but care must be taken of the risk of unwanted cannabimimetic side effects e.g. hypomobility36,37.

Table 1. Relative mRNA abundances of hepatic genes involved in endocannabinoid and fat metabolism. Liver tissue samples were obtained from cows treated with NaCl (n = 7), AEA (n = 7) or 2AG (n = 6) for 9 days. ACAA2, acetyl-CoA acyltransferase 2; ACACA, acetyl-CoA carboxylase alpha; CNR1, cannabinoid receptor 1; CPT1A, carnitine palmitoyltransferase 1A; DGAT1/2, diacylglycerol O-acyltransferase 1/2; FAAH, fatty acid amidase hydrolase; GPR55, G protein-coupled receptor 55; HADH, hydroxyacyl-CoA dehydrogenase; PLAAT5, phospholipase A and acyltransferase 5; MGLL, monoglyceride lipase; PPARA, peroxisome proliferator activated receptor alpha; SREBF1, sterol regulatory element binding transcription factor 1.

Table 2. Plasma anandamide (AEA) and 2-arachidonoylglycerol (2-AG) concentrations (nM) of cows (n = 20) after ad libitum feeding of a grass silage (GS) and corn silage (CS) based diet for 27 days. Data presented as means ± SEM. 1 Data transformed using the Johnson transformation for statistical analysis and back-transformed for interpretation.

Effect of endocannabinoids on plasma lipids. The trend for the lower DMI-normalized FOX after EC treatment was accompanied by a reduction in plasma NEFA concentrations, at least for AEA-treated animals, whereas they increased in control animals. Plasma NEFA concentrations reflect body fat mobilization and function as a quantitative marker for lipolysis in dairy cows23,24. Therefore, it can be assumed that animals of the control group, showing an increase in plasma NEFA concentrations, mobilized some body fat, likely because of stress-induced hypophagia in the respiration chamber. Furthermore, the reduction in plasma NEFA concentrations in AEA-treated animals and the only minimal increase in 2-AG-treated animals might indicate that EC
inhibited lipolysis in these animals despite a slight reduction in feed intake. Similarly, it has been shown that EC signaling activates lipogenic mechanisms\(^{64}\), e.g. CB\(_1\) activation enhanced lipogenesis in primary adipocyte cultures\(^{27}\). However, we did not measure lipolytic activity.

Total plasma fatty acids in cows can be predictive for lipid classes. While C16:0, C18:0 and C18:1\(_\alpha\) are the major fatty acids of the free fatty acid fraction or bound in TG, C18:2\(_\alpha\) is the predominant fatty acid bound in cholesterol esters and phospholipids\(^{65}\). Besides, plasma phospholipids may also contain substantial amounts of C16:0 and C18:0\(^{66}\). Our results of decreasing levels of C16:0, C16:1 and C18:1\(_\alpha\) after AEA and 2-AG administration for 8 days may indicate that EC facilitate the flux of free fatty acids to adipocytes for TG synthesis as described earlier\(^{24,66}\). However, plasma TG concentrations were found not different between control and EC groups. This finding is surprising as it has been reported that pharmacological stimulation of EC signaling increases plasma TG and cholesterol concentrations in mice\(^{67}\). Presumably, hypertriglyceridemia after EC treatment could not be observed in dairy cows as TG were excreted with milk, but this assumption needs further experimental approval. Plasma cholesterol concentrations increased in EC treated animals and in NaCl treated cows on the GS diet, however, they decreased in the control group on the CS diet. These results are in parallel with the stimulatory effect of EC on plasma cholesterol observed in mice\(^{68}\), suggesting reduced plasma lipoprotein clearance and accumulation of plasma lipoproteins in both mice and CS-fed cows. Plasma C18:2\(_\alpha\) decreased in control animals, while EC administration prevented this decrease, which is likely due to the lower feed intake of animals in the control group compared to EC treatment.

**Effect of endocannabinoids on whole-body energy metabolisms.** Previous studies reporting on ECS involvement in whole-body energy metabolism mainly draw conclusions by investigating the role of CB\(_1\) antagonists or CB\(_1\) KO mice\(^{29,30}\). To the best of our knowledge, this is the first study describing the direct effects of i.p. administered AEA and 2-AG on whole-body energy metabolism.

Immediately after i.p. injections and morning feeding, whole body fat oxidation decreased while oxidation of carbohydrates increased in all groups, which is due to the high carbohydrate content in feed. An inverse relationship between COX and FOX, and between FOX and feed intake has been reported earlier for dairy cows\(^{42}\). Accordingly, the higher feed intake after AEA and 2-AG treatment was accompanied by a higher COX, not only after the morning feeding but also in the afternoon. The longer-lasting effect in higher COX can be explained by the fact that more feed ingested with the morning feeding requires longer fermentation and digestion time which in turn delay metabolic CO\(_2\) production from dietary carbohydrates in post-absorptive metabolic processes. In parallel to the short-term response in feed intake after EC injection, the reduction in FOX was most pronounced in the first two hours after injection. Both FOX and COX contribute to total metabolic HP since the portion of heat produced from COX is higher than from FOX, and since COX and feed intake were higher in EC- compared to NaCl-treated cows, the resulting metabolic HP was higher in AEA and 2-AG treated animals.

To account for the differences in feed and energy intake between treatment groups and to examine whether changes were limited to a feed intake-related effect, daily FOX, COX and metabolic HP were additionally normalized to DMI. The analysis revealed that double normalized FOX tended to be lower in the AEA and 2-AG compared to the control group, suggesting that effects extend beyond differences in feed intake and that AEA and 2-AG suppress whole-body fat catabolism and/or increase lipogenesis. These findings support earlier indirect calorimetry studies reporting that the CB\(_1\) antagonist rimonabant increased energy expenditure in rats by increasing fat oxidation\(^{29,30}\). From these studies and since endocannabinoids were reported to favor anabolic processes\(^{26,68}\), we expected double normalized metabolic HP to be reduced in the AEA and 2-AG compared to the control group, but the EC effect could not be tested significantly lower. Apparently, the numeric increase in DMI-normalized COX overrides the tending FOX decrease induced by EC.

**Effect of endocannabinoids on hepatic gene expression.** The expression of hepatic genes involved in the ECS and fat metabolism were not different between treatment groups. Our results are in contrast to studies performed in mice, where CB\(_1\) activation increased de novo fatty acid synthesis and increased hepatic gene expression of genes involved in lipogenesis, such as SREBP-1, ACC1 and FAS\(^{38}\). In contrast to monogastric species, the bovine liver is only marginally capable to perform de novo fatty acid synthesis because of limited ACC abundance, whereas adipose tissue accounts for over 92% of whole-body fatty acid synthesis\(^{69}\). The lack of expression changes were even lower with CS feeding. Although we found numerically higher plasma C18:2\(_\alpha\) content in animals fed the CS diet (data not shown), plasma AEA concentrations were comparable between, and 2-AG plasma concentrations were even lower with CS feeding. Presumably, the 30% difference in the dietary linoleic acid content was not large enough to induce differences in plasma EC concentrations. This conclusion is supported by earlier studies reporting approximately twofold higher tissue EC levels with feeding an eightfold higher linoleic acid content\(^{14,50}\). However, the tending lower plasma 2-AG concentrations with CS feeding might be explained by the higher content n-3 PUFA, known to reduce the EC tone\(^{56}\), yet it remains questionable why this difference is not observed for AEA. Besides the different amounts of some constitutive in the rations, a major reason might be the lower energy intake of the animals on the GS diet, as the reduction of energy intake has been shown to stimulate 2-AG biosynthesis\(^{41}\).
Conclusion
The present study demonstrates that i.p. administration of AEA and 2-AG reduces the stress-induced suppression of feed intake and stimulates feed intake in the short-term. As a consequence of the latter, both EC increase whole-body carbohydrate oxidation and metabolic heat production. EC administration reduces whole-body fat oxidation exceeding differences in feed intake, suggesting that AEA and 2-AG suppress whole-body fat catabolism and/or support lipogenesis. However, once daily EC administration does not affect plasma TG concentrations, hepatic lipogenesis and hepatic fatty acid oxidation in dairy cows. Future studies should also determine if higher EC dosages, multiple injections per day or continuous EC infusion would alter feed intake and metabolism in the long-term. Finally, feeding a corn silage based diet with a 30% higher linoleic acid content than grass silage did not increase plasma EC concentrations, thus more research is required to elucidate how diet formulation can modulate the EC tone in ruminants.

Data availability
All data generated and analyzed are available from the corresponding author on request.

Received: 21 May 2021; Accepted: 24 November 2021
Published online: 08 December 2021

References
1. Buch, C. et al. Endocannabinoids produced by white adipose tissue modulate lipolysis in lean but not in obese rodent and human. Front. Endocrinol. (Lausanne) 12, 716431. https://doi.org/10.3389/fendo.2021.716431 (2021).
2. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 66, 101–121. https://doi.org/10.1054/plef.2001.0341 (2002).
3. Brown, A. J. Novel cannabinoid receptors. Br. J. Pharmacol. 152, 567–575. https://doi.org/10.1038/sj.bjp.0707481 (2007).
4. Willoughby, K. A., Moore, S. F., Martin, B. R. & Ellis, E. F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282, 243–247 (1997).
5. Jarai, Z. et al. Cardiovascular effects of 2-arachidonoylglycerol in anesthetized mice. Hypertension 35, 679–684. https://doi.org/10.1161/01.hyp.35.2.679 (2000).
6. Ruiz de Azua, J. I. & Lutz, B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell. Mol. Life Sci. CMLS 76, 1341–1363. https://doi.org/10.1007/s00018-018-2994-6 (2019).
7. Willoughby, K. A., Moore, S. F., Martin, B. R. & Ellis, E. F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282, 243–247 (1997).
8. Kirkham, T. C. & Williams, C. M. Endogenous cannabinoids and appetite. Nat. Rev. Res. 14, 65–86. https://doi.org/10.1038/ntrr20118 (2001).
9. Avraham, Y., Putsarsi, I., Magen, L., Vorobiev, L. & Berry, E. M. 2-Arachidonoylglycerol as a possible treatment for anorexia nervosa in animal model in mice. Brain Res. 1670, 185–190. https://doi.org/10.1016/j.brainres.2017.06.003 (2017).
10. Cavuoto, P. & Wittert, G. A. The role of the endocannabinoid system in the regulation of energy expenditure. Best Pract. Res. Clin. Endocrinol. Metab. 23, 79–86. https://doi.org/10.1016/j.beem.2008.10.005 (2009).
11. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134, 1151–1154. https://doi.org/10.1038/sj.bjp.0704379 (2001).
12. Kirkham, T. C., Williams, C. M., Fezza, F. & Di Marzo, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoylglycerol. Br. J. Pharmacol. 136, 550–557. https://doi.org/10.1038/sj.bjp.0704767 (2002).
13. Gomez, R. et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. Off. J. Soc. Neurosci. 22, 9612–9617 (2002).
14. Fride, E. & Mechoulam, R. Pharmacological activity of the cannabinoid receptor agonist anandamide, a brain constituent. Eur. J. Pharmacol. 231, 313–314. https://doi.org/10.1016/0014-2999(93)90468-w (1993).
15. Bursyha, G., Varró, A., Dimény, R., Thompson, D. G. & Dockray, G. J. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G63–G69. https://doi.org/10.1152/ajpgi.00059.2010 (2010).
16. Storr, M. A. & Sharkey, K. A. The endocannabinoid system and gut-brain signalling. Curr. Opin. Pharmacol. 7, 575–582. https://doi.org/10.1016/j.coph.2007.08.008 (2007).
17. DiPatrizio, N. V. Endocannabinoids in the Gut. Cannabis Cannabinoid Res. 1, 67–77. https://doi.org/10.1089/can.2016.0001 (2016).
18. Alvheim, A. R. et al. Dietary linoleic acid elevates the endocannabinoids 2-AG and anandamide and promotes weight gain in mice fed a low fat diet. Lipids 49, 59–69. https://doi.org/10.1007/s11745-013-3842-y (2014).
19. Ghosh, S. et al. Linoleic acid in diets of mice increases total endocannabinoid levels in bowel and liver: Modification by dietary glucose. Obes. Res. Sci. Pract. 5, 383–394. https://doi.org/10.1002/osp4.344 (2019).
20. Watanabe, S., Doshi, M. & Hamazaki, T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot. Essent. Fatty Acids 69, 51–59. https://doi.org/10.1016/j.proag.2003.0952-3278(03)00056-5 (2003).
21. Hill, M. N. & Tasker, J. G. Endocannabinoid signalling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic–pituitary–adrenal axis. Neuroscience 204, 5–16. https://doi.org/10.1016/j.neurosci.2011.12.030 (2012).
22. Patel, S., Roelke, C. T., Rademacher, D. J. & Hillard, C. J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 21, 1057–1069. https://doi.org/10.1111/j.1460-9568.2005.03916.x (2005).
23. Hill, M. N. et al. Endocannabinoid signalling is essential for stress adaptation. Proc. Natl. Acad. Sci. U. S. A. 107, 9406–9411. https://doi.org/10.1073/pnas.0914661107 (2010).
24. Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E. & Hillard, C. J. Endocannabinoid signalling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145, 5431–5438. https://doi.org/10.1210/endo.2004-0638 (2004).
25. Surkin, P. N. et al. Pharmacological augmentation of endocannabinoid signalling reduces the neuroendocrine response to stress. Psychoneuroendocrinology 87, 131–140. https://doi.org/10.1016/j.psyneuen.2017.10.015 (2018).
26. Kunos, G., Osei-Hyiaman, D., Liu, J., Godlewski, G. & Batkai, S. Endocannabinoids and the control of energy homeostasis. J. Biol. Chem. 283, 33021–33025. https://doi.org/10.1074/jbc.R800012200 (2008).
27. Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Investig. 112, 423–431. https://doi.org/10.1172/jci77725 (2003).
28. Osei-Hyiaman, D. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Investig. 115, 1298–1305. https://doi.org/10.1172/jci123057 (2005).
31. Myers, M. N., Zachut, M., Tam, J. & Contreras, G. A. A proposed modulatory role of the endocannabinoid system on adipose tissue metabolism and appetite in periparturient dairy cows. J. Anim. Sci. Biotechnol. 12, 21. https://doi.org/10.1186/s41064-021-00549-3 (2021).

32. Zachut, M. et al. Characterization of the endocannabinoid system in subcutaneous adipose tissue in periparturient dairy cows and its association to metabolic profiles. PLoS ONE 13, e0205996. https://doi.org/10.1371/journal.pone.0205996 (2018).

33. Kuhla, B., Kaever, V., Tuchscherer, A. & Kuhla, A. Involvement of plasma endocannabinoids and the hypothalamic endocannabinoid system in increasing feed intake after parturition of dairy cows. Neuropeptides 53, 147–156 (2020).

34. Khan, M. J., Graugnard, D. E. & Loor, J. J. Endocannabinoid system and proopiomelanocortin gene expression in peripartal bovine liver in response to perpartal plane of nutrition. J. Anim. Physiol. Anim. Nutr. (Berl) 96, 907–919. https://doi.org/10.1111/j.1439-0436.2011.01204.x (2012).

35. Hao, S., Avraham, Y., Mechoulam, R. & Berry, E. M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur. J. Pharmacol. 392, 147–156 (2000).

36. Sulcova, E., Mechoulam, R. & Fride, E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59, 347–352. https://doi.org/10.1016/S0301-0535(97)00422-2 (1998).

37. Long, J. Z. et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5, 37–44. https://doi.org/10.1038/nchembio.129 (2009).

38. Di Patrizio, N. V. Endocannabinoids and the gut-brain control of food intake and obesity. Nutrients https://doi.org/10.3390/nu13041214 (2021).

39. Derno, M., Elsner, H. G., Paetow, E. A., Scholze, H. & Schweigel, M. Technical note: a new facility for continuous respiration measurements in lactating cows. J. Dairy Sci. 92, 2804–2808. https://doi.org/10.3168/jds.2008-1839 (2009).

40. Chwalibog, A., Jensen, K. & Thorbek, G. Oxidation of nutrients in bull calves treated with beta-adrenergic agonists. J. Anim. Sci. Biotechnol. 9, 1202–1206 (2018).

41. Dijkstra, J. Diet effects on urine composition of cattle and N2O emissions. Animal 7(Suppl 2), 292–302. https://doi.org/10.1017/s1751731113000578 (2013).

42. GF. New equations for predicting metabolisable energy of compound feeds for cattle. J. Dairy Sci. 91, 2557–2566. https://doi.org/10.3168/jds.2012-5727 (2013).

43. Frayn, K. N. Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 55, 628–634. https://doi.org/10.1152/jappl.1983.55.5.628 (1983).

44. Brouwer, E. Report of sub-committee on constants and factors. Pages 441–443 in Proceedings of the 3rd Symposium on Energy Metabolism, no. 11 K. L. Blaxter, ed. EAAP. Academic Press, London, UK. (1965).

45. Brouwer, E. Report of sub-committee on constants and factors. Pages 916–920 in Proceedings of the 4th Symposium on Energy Metabolism, no. 45 K. L. Blaxter, ed. EAAP. Academic Press, London, UK. (1967).

46. GfE. Metabolism, no. 11 K. L. Blaxter, ed. EAAP. Academic Press, London, UK. (1965).

47. Kalbe, C., Priepke, A., Nürnberg, G. & Dannenberger, D. Effects of long-term microalgae supplementation on muscle microstructure, meat quality and fatty acid composition in growing pigs. J. Anim. Physiol. Anim. Nutr. (Berl) 103, 574–582. https://doi.org/10.1111/j.1740-0929.2011.01307.x (2019).

48. Sukhiya, P. S. & Palmquist, D. Rapid method for determination of total fatty acid content and composition of feeds and feces. J. Agric. Food Chem. 36, 1202–1206 (1988).

49. Dannenberger, D., Nuernberg, K., Nuernberg, G. & Priepke, A. Different dietary protein and PUFA interventions alter the fatty acid composition, but not the meat quality, of porcine muscle. Nutrients 4, 1237–1246. https://doi.org/10.3390/nu40901477 (2012).

50. GF. Vol. No. 8 (DLG-Verlag, Frankfurt am Main, Germany). (2001).

51. Dannenberger, D. et al. Effects of diets supplemented with n-3 or n-6 PUFA on pig muscle lipid metabolites measured by non-targeted LC-MS lipidomic profiling. J. Food Compos. Anal. 56, 47–54. https://doi.org/10.1016/j.jfca.2016.11.015 (2017).

52. Zoerner, A. A. et al. Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. J. Chromatogr. A 1202–1206 (2008).

53. Ulrich-Lai, Y. M., Fulton, S., Wilson, M., Petrovich, G. & Rinaman, L. Stress exposure, food intake and emotional state. Stress 18, 381–399. https://doi.org/10.3109/10253890.2015.1062981 (2015).

54. Manisalcio, J. W. & Rinaman, L. Interceptive modulation of neuroendocrine, emotional, and hypogastic responses to stress. Physiol. Behav. 176, 195–206. https://doi.org/10.1016/j.physbeh.2017.01.027 (2017).

55. Szczeni, O. et al. Effect of restraint stress on plasma concentrations of cortisol, progesterone and pregnancy associated-glycoprotein-1 in pregnant heifers during late embryonic development. Theriogenology 76, 1380–1385. https://doi.org/10.1016/j.theriogenology.2011.05.030 (2011).

56. Rademacher, D. J. & Hillard, C. J. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 633–641. https://doi.org/10.1016/j.pnpbp.2006.12.013 (2007).

57. Gorszka, B. B., Hill, M. N. & Hillard, C. J. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosci. Biobehav. Rev. 32, 1152–1160. https://doi.org/10.1016/j.neubiorev.2008.03.004 (2008).

58. Kozak, K. R. et al. Metabolism of prostaglandin glycerol esters and prosta-glandin ethanolamides in vitro and in vivo. J. Biol. Chem. 276, 36993–36998. https://doi.org/10.1074/jbc.M108584200 (2001).

59. van Ackern, I., Kuhla, A. & Kuhla, A. A role for peripheral anandamide and 2-arachidonoylglycerol in short-term food intake and orexigenic hypothalamic responses in a species with continuous nutrient delivery. Nutrients 13, 3587. https://doi.org/10.3390/nu13103587 (2021).

60. Bobe, G., Young, J. W. & Betz, D. C. Invited review: pathology, etiology, prevention, and treatment of fatty liver in dairy cows. J. Dairy Sci. 87, 3105–3124. https://doi.org/10.3168/jds.s0022-0302(04)73436-3 (2004).

61. Pettit, H. V., Palim, M. F. & Doepel, L. Hepatic lipid metabolism in transition dairy cows fed flaxseed. J. Dairy Sci. 90, 4780–4792. https://doi.org/10.3168/jds.2007-0066 (2007).

62. Vertor, R. & Pagano, C. The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. Best Pract. Res. Clin. Endocrinol. Metab. 23, 51–53. https://doi.org/10.1016/j.beem.2008.10.002 (2009).

63. Tessari, R. et al. Changes of plasma fatty acids in four lipid classes to understand energy metabolism at different levels of non-esterified fatty acid (NEFA) in dairy cows. Animals https://doi.org/10.3390/ani10081410 (2020).
66. Bellocchio, L., Cervino, C., Vicennati, V., Pasquali, R. & Pagotto, U. Cannabinoid type 1 receptor: Another arrow in the adipocytes’ bow. J. Neuroendocrinol. 20(Suppl 1), 130–138. https://doi.org/10.1111/j.1365-2826.2008.01682.x (2008).

67. Ruby, M. A. et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc. Natl. Acad. Sci. 105, 14561–14566. https://doi.org/10.1073/pnas.0807232105 (2008).

68. Richard, D., Guesdon, B. & Timofeeva, E. The brain endocannabinoid system in the regulation of energy balance. Best Pract. Res. Clin. Endocrinol. Metab. 23, 17–32. https://doi.org/10.1016/j.beem.2008.10.007 (2009).

69. Ingle, D. L., Bauman, D. E. & Garrigus, U. S. Lipogenesis in the ruminant: in vivo site of fatty acid synthesis in sheep. J. Nutr. 102, 617–623. https://doi.org/10.1093/jn/102.5.617 (1972).

70. Alvheim, A. R. et al. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity (Silver Spring) 20, 1984–1994. https://doi.org/10.1038/oby.2012.38 (2012).

71. DiPatrizio, N. V. et al. Fasting stimulates 2-AG biosynthesis in the small intestine: Role of cholinergic pathways. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309, R805-813. https://doi.org/10.1152/ajpregu.00239.2015 (2015).

Acknowledgements
We gratefully thank H. Brandt, R. Fürstenberg, Dr. M. Derno and the staff of the “Tiettechnikum” and the Experimental Cattle Facility at the Research Institute for Farm Animal Biology (FBN) Dummerstorf for assistance in animal care and handling, respiration chamber measurements, and sample preparation. We also thank K. Kennedy for statistical advice. We would further like to acknowledge the Research Service Centre Metabolomics at the Hannover Medical School for endocannabinoid analysis. Part of this work financially supported by funds of the German Government’s Special Purpose Fund held at Landwirtschaftliche Rentenbank (eMissionCow). Other project parts were funded by the Deutsche Forschungsgemeinschaft (German Research Foundation), project No. 416735196 (KU 1956/6-1) and the core budget of the FBN.

Author contributions
The authors’ contributions were as follows: I.v.A. conducted the animal experiment, provided medical care, performed statistical evaluation, and designed graphs and tables. A.T. developed the statistical models. R.W. and D.D. performed lipid extraction and GC-FID analysis. I.v.A. and B.K. wrote the manuscript. B.K. designed and conducted the animal experiment. All authors approved the final manuscript as submitted.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-02970-0.

Correspondence and requests for materials should be addressed to B.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021